ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. The company is headquartered in Burlingame, California. Show more

323 ALLERTON AVENUE, SOUTH SAN FRANCISCO, CA, UNITED STATES, 94080, South San Francisco, CA, 94080, USA

https://www.alxoncology.com

BIOTECHNOLOGY

HEALTHCARE

Start AI Chat

Market Cap

262.7M

52 Wk Range

$1.02 - $2.66

Previous Close

$1.84

Open

$1.85

Volume

1,061,557

Day Range

$1.81 - $1.92

Enterprise Value

148M

Cash

22.69M

Avg Qtr Burn

-16.06M

Insider Ownership

0.89%

Institutional Own.

84.59%

Qtr Updated

06/30/26

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Evorpacept (ALX148) + Trastuzumab + Chemotherapy (CD47 Blocker) Details Breast Cancer, Cancer	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Evorpacept (ALX148) + rituximab and lenalidomide Details Non-Hodgkin lymphoma	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Evorpacept (ALX148) + Herceptin® (trastuzumab)+Cyramza® (ramucirumab) and paclitaxel Details Cancer, Gastric cancer	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Evorpacept + cetuximab + pembrolizumab Details Cancer, Metastatic colorectal cancer	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Evorpacept (ALX148) + Sarclisa Details Cancer, Multiple myeloma	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Evorpacept (ALX148) + Zanidatamab Details Breast cancer, Cancer	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Evorpacept + enfortumab vedotin-ejfv/PADCEV® Details Cancer, Urothelial cancer	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ALX2004 Details EGFR-expressing solid tumors	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Evorpacept (ALX148) + ENHERTU® Details Breast cancer, Cancer	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Evorpacept (ALX148) + Venetoclax Details Cancer, Acute myeloid leukemia	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Evorpacept (ALX148) + Keytruda Details Head and neck cancer, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Evorpacept (ALX148) + Keytruda Details Cancer, Platinum-resistant ovarian cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Evorpacept (ALX148) combo w/ azacitidine Details Myelodysplastic syndrome, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.